Skip to main content
SpringerLink
Log in

Staging and Prognosis in Lung Cancer: Making the Complex Accessible

  • Chapter
Thoracic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 105))

Abstract

Long-term survival in lung cancer remains relatively dismal (1). With the exception of resectable patients with either minimal or no node involvement, selected locally advanced patients with NSCLC, and selected limited disease patients with SCLC, cure remains elusive (2,3). As we tease out those who may benefit from aggressive therapy, the intricacies of the staging system appear to grow inversely proportional to the prospect of cure using conventional therapeutic maneuvers. Therapeutic nihilists would argue that staging, in such a setting, is largely irrelevant or useless. However, the nuances of treatment hinge directly on appropriate staging. In addition, carefully defined staging constitutes a common language for clinicians, particularly in the interdisciplinary setting which ideally is required for the optimal treatment of lung cancer. For staging to be meaningful, it must be methodical, comprehensive and reproducible. Otherwise, the putative stage assignment is meaningless.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Denoix PF. Enquete permanent dans les centres anticancereux. Bull Inst Nat Hyg 1: 70–75, 1946.

    Google Scholar 

  2. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 45: 8–30, 1995.

    Article  PubMed  CAS  Google Scholar 

  3. Martini N. Operable lung cancer. CA Cancer J Clin 43: 210–214, 1993.

    Article  Google Scholar 

  4. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626, 1991.

    PubMed  CAS  Google Scholar 

  5. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13: 1221–1230, 1995.

    PubMed  CAS  Google Scholar 

  6. Mountain CF, Can DT, Anderson WAD. A system for the clinical staging of lung cancer. AJR 120: 130–138, 1974.

    CAS  Google Scholar 

  7. Mountain CF. A new international staging system for lung cancer. Chest 89: 255s-s335, 1986 (supplement).

    Google Scholar 

  8. Mountain CF. Revision in the international staging system for staging lung cancer. Chest 111: 1710–1717, 1997.

    Article  PubMed  CAS  Google Scholar 

  9. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96: 440–447, 1988.

    PubMed  CAS  Google Scholar 

  10. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55: 51–56, 1995.

    PubMed  CAS  Google Scholar 

  11. Treasure T, Belcher JR. Prognosis of peripheral lung tumours related to size of the primary. Thorax 36: 5–8, 1981.

    Article  PubMed  CAS  Google Scholar 

  12. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Iwa T, Nonomura A, Kamimura R, Takashima T. Proposals regarding some deficiencies in the new international staging system for non-small cell lung cancer. Jpn J Clin Oncol 21: 160–168, 1991

    PubMed  CAS  Google Scholar 

  13. Mountain CF. Expanded possibilities for surgical treatment of lung cancer. Survival in Stage IIIA disease. Results of surgical treatment in patients with Stage IIIA non-small cell lung cancer. Chest 97: 1045–1051, 1990.

    Article  PubMed  CAS  Google Scholar 

  14. Watanabe Y, Shimizu J, Oda M, et al. Results of surgical treatment in patients with stage IIIA non-small cell lung cancer. Thorac Cardiovasc Surgeon 39:44–49, 1991.

    Article  CAS  Google Scholar 

  15. Deslauriers J, Brisson J, Cartier R, Marcien F, Gagnon D, Piraux M, Beaulieu M. Carcinoma of the lung: Evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 97: 504–512, 1989.

    PubMed  CAS  Google Scholar 

  16. Shimizu N, Ando A, Date H, Teramoto S. Prognosis of undetected intrapulmonary metastases in resected lung cancer. Cancer 71(12): 3868–3872, 1993.

    Article  PubMed  CAS  Google Scholar 

  17. Mountain CF. Prognostic implications of the international staging system for lung cancer. Semin Oncol 15(3): 236–245, 1988.

    PubMed  CAS  Google Scholar 

  18. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3: 47–50, 1997.

    PubMed  CAS  Google Scholar 

  19. Rosvold E, Langer CJ, McAleer C, Zipin H, Bonjo C, Ozols R. Advancing age does not exacerbate toxicity or compromise outcome in non-small cell lung cancer patients receiving paclitaxel-carboplatin. Proc Am Soc Clin Oncol 18: 478a, 1999 (abstract A-1846).

    Google Scholar 

  20. Akaogi E, Mitsui K, Onizuka M, Ishikawa S, Tsukada H, Mitsui T. Pleural dissemination in non-small cell lung cancer: Results of radiological evaluation and surgical treatment. J Surg Oncol 57: 33–39, 1994.

    Article  PubMed  CAS  Google Scholar 

  21. Shimizu J, Oda M, Morita K, Hayashi Y, Arano Y, Matsumoto I, Kobayashi K, Nonomura A, Watanabe Y. Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. J Surg Oncol 61: 1–6, 1996.

    Article  PubMed  CAS  Google Scholar 

  22. Thomas PA, Piantadosi S. Postoperative T1N0 non-small cell lung cancer: squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 94: 349–354, 1987.

    Google Scholar 

  23. Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, Holmes EC, Lukeman JM, Mountain CF, Oldham RK, Pearson RG, Wright PW, Lake WH, Lung Cancer Study Group. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 54: 1802–1813, 1984.

    Article  PubMed  CAS  Google Scholar 

  24. Williams DE, Pairolero PC, Davis CS, Bernatz PE, Payne WS, Taylor WF, Uhlenhopp MA, Fontana RS. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 82: 70–76, 1981.

    PubMed  CAS  Google Scholar 

  25. Dresler C, Ritter J, Wick M. Clinical and pathological findings in large cell lung carcinoma with neuroendocrine differentiation. Proc Am Soc Clin Oncol 14: A1096, 1996.

    Google Scholar 

  26. Lipford HH, Scacs DL, Eggleston JC, More CW, Littlemore KD, Baker RR. Prognostic factors in surgically resected limited stage, non-small cell lung cancer. Am J Surg Pathol 8: 357–365, 1984.

    Article  PubMed  Google Scholar 

  27. Soorensen JB, Badsberg JH. Prognostic factors in resected stage I and II adenocarcinoma of the lung: A multivariate analysis of 137 consecutive patients. J Thorac Cardiovasc Surg 99: 218–226, 1990.

    Google Scholar 

  28. Green N, Kurohara SS, George FW. Cancer of the lung: an in-depth analysis of prognostic factors. Cancer 28: 1229, 1971.

    Article  PubMed  CAS  Google Scholar 

  29. Lanzotti VJ, Thomas DR, Boyle LE, et al. Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 39: 303, 1977.

    Article  PubMed  CAS  Google Scholar 

  30. Miller TP, Chen TT, Coltman CA, et al. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group study. J Clin Oncol 4: 502–508, 1986.

    PubMed  CAS  Google Scholar 

  31. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell 1 ung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 4: 702–709, 1986.

    PubMed  CAS  Google Scholar 

  32. Einhorn LE, Loehrer PJ, Williams SD, et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small cell lung cancer. J Clin Oncol 4: 1037–1043, 1986.

    Google Scholar 

  33. Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small cell lung cancer. J Clin Oncol 5: 113–124, 1987.

    PubMed  CAS  Google Scholar 

  34. O’Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 4: 1604–1614, 1986.

    PubMed  Google Scholar 

  35. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633–641, 1988.

    PubMed  CAS  Google Scholar 

  36. Sukurai M, Shinkai T, Eguchi K, et al. Prognostic factors in non-small cell lung cancer; multiregression analysis in the National Cancer Center Hospital(Japan). J Cancer Res Clin Oncol 115: 563–566, 1987.

    Article  Google Scholar 

  37. Soorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung: a mulivariate regression analysis of 259 patients. Cancer Res 49: 5748–5754, 1989.

    Google Scholar 

  38. Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic factor risk index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30: 1–6, 1992.

    Article  PubMed  CAS  Google Scholar 

  39. Kojima A, Shinkai T, Eguchi K, et al. Analysis of three-year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J Clin Oncol 21: 276–281, 1991.

    PubMed  CAS  Google Scholar 

  40. Kawahara M, Furuse K, Kodama N, et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68: 714–719, 1991.

    Article  PubMed  CAS  Google Scholar 

  41. Bonomi P, Gale M, Rowland K, et al. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 20: 247–252, 1991.

    Article  PubMed  CAS  Google Scholar 

  42. O’Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pre-treatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4: 1604–1614,1986.

    PubMed  Google Scholar 

  43. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 65: 25, 1980.

    PubMed  CAS  Google Scholar 

  44. Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992. Proc Am Soc Clin Oncol 17: 461A, 1998.

    Google Scholar 

  45. Elson CE, Roggli VL, Vollmer RT, et al. Prognostic indicators for survival in stage I carcinoma of lung. A histologic study of 47 cases. Mod Pathol 1: 288–291, 1988.

    PubMed  CAS  Google Scholar 

  46. Shahab I, Fraire AE, Greenberg SD, et al. Morphometric quantitation of tumor necrosis in stage I non-small cell carcinoma of lung: prognostic implications. Mod Pathol 5: 521–524, 1992.

    PubMed  CAS  Google Scholar 

  47. Ten Velde GP, Havenith MG, Volovics A, Bosman FT. Prognostic significance of basement membrane deposition in operable squamous cell carcinomas of the lung. Cancer 67: 3001–3005, 1991.

    Article  PubMed  CAS  Google Scholar 

  48. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer 10: 21–33, 1993.

    Article  PubMed  CAS  Google Scholar 

  49. Rice TW, Tubbs RR, Hoeltge GA, Kirby TJ, Meeker DP, Medendorp SV, Bukowski RM. Expression of blood group antigen A by stage I non-small cell lung carcinomas. Ann Thorac Surg 59: 568–572, 1995.

    Article  PubMed  CAS  Google Scholar 

  50. Dresler CN, Ritter JH, Wick MR, Roper CL, Patterson GA, Cooper JD. Immunostains for blood group antigens lack prognostic significance in Ti lung carcinoma. Ann Thorac Surg 59: 1069–1073, 1995.

    Article  PubMed  CAS  Google Scholar 

  51. Orntoft TF, Wolf H, Clausen H, Dabelsteen E, Hakomori SI. Blood group ANHrelated antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas. Int J Cancer 43: 774–780, 1989.

    Article  PubMed  CAS  Google Scholar 

  52. Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Ley/Lebantigens with survival in patients with carcinoma of the lung. N Engl J Med 327: 14–18, 1992.

    Article  PubMed  CAS  Google Scholar 

  53. Pantel K, Passlick B, Izbicki JR, Liewald R, Karg O, Riethmuller G. Expression of Lewis Y blood group precursor antigens on non-small cell lung carcinomas is associated with an unfavorable prognosis. Proc Am Soc Clin Oncol 12: 290, 1993.

    Google Scholar 

  54. Ogawa J, Sano A, Inoue H, Kolde S. Expression of Lewis-related antigen and prognosis in stage 1 non-small cell lung cancer. Ann Thorac Surg 59: 412–415, 1995.

    Article  PubMed  CAS  Google Scholar 

  55. Lee JS, Hong WK. Prognostic factors in lung cancer. N Engl J Med 327: 47–48, 1992.

    Article  Google Scholar 

  56. Lee JS, Ro JY, Sabin AA, et al. Expression of blood group antigen A: a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 324: 1084–1090, 1991

    Article  Google Scholar 

  57. Matsumoto H, Muramatsu H, Shimotakahara T, et al. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer 72: 75–81, 1993.

    Article  PubMed  CAS  Google Scholar 

  58. Volm M, Hahn EW, Mattern J, et al. Five year follow up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell carcinoma. Cancer Res 48: 2923–2928, 1988.

    PubMed  CAS  Google Scholar 

  59. Miyamoto H, Harada M, Isobe A, et al. Prognostic value of nuclear DNA content and expression of therasoncogene product in lung cancer. Cancer Res 51: 6346–6350, 1991.

    Google Scholar 

  60. Zimmerman PV, Hawson GAT, Bint MH, Parsons PG. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 2: 530–533, 1987.

    Article  PubMed  CAS  Google Scholar 

  61. Zimmerman PV, Bint MH, Hawson GAT, et al. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 530, 1987.

    Google Scholar 

  62. Sahin A, Lee JS, Ro JY, et al. DNA flow cytometric (FCM) analysis of non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 8: 226, 1989.

    Google Scholar 

  63. Rodenhuis S, Van De Wetering MLM, Mooi WJ, Evers SG, van Zandwiijk N, Bos JL. Mutational activation of theK-rasoncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929–935, 1989.

    Article  Google Scholar 

  64. Rodenhuis S, Slebos RJC, Boot AJM, Evers SG, Mooi WJ, Wagenaar SSC, van Bodegom PC, Bos JL. Incidence and possible clinical significance ofK-rasoncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738–5741, 1988.

    PubMed  CAS  Google Scholar 

  65. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T.rasgene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903–2906, 1992.

    PubMed  CAS  Google Scholar 

  66. Mitsudomi T, Steinberg SM, Oie HK, Mulshine J, Phelps R, Viallet J, Pass H, Minna JD, Gazdar AF.Rasgene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51: 4999–5002, 1991.

    PubMed  CAS  Google Scholar 

  67. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations ofrasgenes distinguish a subset of non-small cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353–1362, 1991.

    PubMed  CAS  Google Scholar 

  68. Rosell R, Molina F, Moreno I, Martinez E, Pifarre A, Font A, Li S, Skacel Z, Gomez-Codina J, Camps C, Monzo M, de Anta JM. MutatedK-rasgene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 12: S59–S70, 1995.

    Article  PubMed  Google Scholar 

  69. Keohavong P, De Michele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Sigfried JM. Detection ofK-rasmutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2: 411–418, 1996.

    PubMed  CAS  Google Scholar 

  70. Martinez E, Vadell C. Clinical implications of genotypic characterization of non-small cell lung cancer based onK-rasmutants. Proc Am Soc Clin Oncol 13: 325, 1994.

    Google Scholar 

  71. Rodenhuis S, Slebos RJC. Clinical significance ofrasoncogene activation in human lung cancer. Cancer Res 52: 2665S–2669S, 1992 (suppl).

    PubMed  CAS  Google Scholar 

  72. Weiner DB, Norberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA, Kern JA. Expression of the neu gene encoded protein (pl 85“”) in human non-small cell carcinomas of the lung. Cancer Res 50: 421–425, 1990.

    PubMed  CAS  Google Scholar 

  73. Noguchi M, Murakami M, Bennett W, Lupu R, Hui F, Harris CC, Gerwin BI. Biological consequences of overexpression of a transfectedc-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res 53: 2035–2043, 1993.

    PubMed  CAS  Google Scholar 

  74. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value ofc-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372–1375, 1991.

    Article  PubMed  CAS  Google Scholar 

  75. Scagliotti GV, Leonardo E, Cappia S, Masiero P, Micela M, Gubetta L, Pozzi E. Epidermal growth factor receptor and neu-oncogene expression in lung cancer. Proc Am Soc Clin Oncol 12: 328, 1993.

    Google Scholar 

  76. Kern J, Slebos R, Top B, Rodenhuis S, Lager D, Robinson R, Weiner D, Schwartz DA.C-erbB-2 expression and codon 12K-rasmutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516–520, 1994.

    Article  PubMed  CAS  Google Scholar 

  77. Volm M, Drings P, Wodrich W. Prognostic significance of the expression ofcfos c-junandc-erb B-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 119: 507–510, 1993.

    Article  PubMed  CAS  Google Scholar 

  78. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13: 1009–1022, 1995.

    PubMed  CAS  Google Scholar 

  79. Fung CY, Fisher DE. p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 13: 808–811, 1995.

    PubMed  CAS  Google Scholar 

  80. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675–679, 1990.

    Article  PubMed  CAS  Google Scholar 

  81. Chiba I, Takahashi T, Nau MM, D’Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon W, Holmes EC, Ninna JD. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603–1610, 1990.

    PubMed  Google Scholar 

  82. Mitsudomi T, Lyama T, Kusano T, Ohsaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. Proc Am Assoc Cancer Res 34: 516, 1993 (abstract).

    Google Scholar 

  83. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest 106: 377S–381S, 1994.

    Article  PubMed  CAS  Google Scholar 

  84. Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res 83: 101–106, 1992.

    Article  PubMed  CAS  Google Scholar 

  85. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828–4831, 1992.

    PubMed  CAS  Google Scholar 

  86. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66: 735–738, 1992.

    Article  PubMed  CAS  Google Scholar 

  87. Passlick B, Izbicki JR, Haussinger K, Thetter O, Pantel K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J Thorac Caradiovasc Surg 109: 1205–1211, 1995.

    Article  CAS  Google Scholar 

  88. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong KH. Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893–1903, 1995.

    Google Scholar 

  89. Top B, Mooi WJ, Klaver SG, Boerrigter L, Wisman P, Elbers HRJ, Visser S, Rodenhuis S. Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int J Cancer 64: 83–91, 1995.

    Article  PubMed  CAS  Google Scholar 

  90. Shirotani Y, Hiyama K, Ishioka S, et al. Alteration in length of telomeric repeats in lung cancer. Lung Cancer 11: 29–41, 1994.

    Article  PubMed  CAS  Google Scholar 

  91. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, et al. P21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 3(10): 1831–1835, 1997.

    PubMed  CAS  Google Scholar 

  92. Kwiatkowski DJ, Harpole PH, Jr; Godleski J, Herndon JE, 2nd; Shieh DB, Richards W, Blanco R, Xu HJ, Strauss GM, Sugarbaker DJ. Molecular pathologic substaging in 244 stage I NSCLC patients: clinical implications. J Clin Oncol 7: 16(7): 2468–2477, 1998.

    CAS  Google Scholar 

  93. Kim Y-C, Kyung J, Park O, Kern JA, Park C-S, Lim S-C, Jang A-S, Yang J-B. The interactive effect of ras, her-2, p53, and BCL-2 expression in predicting survival of non-small cell lung cancer patients. Lung Cancer 22: 181–190, 1998.

    Article  PubMed  CAS  Google Scholar 

  94. Keogan MT, Tung KT, Kaplan DK, Goldstraw PJ, Hansell DM. The significance of pulmonary nodules detected on CT staging for lung cancer. Clin Radiology 48: 94–96, 1993.

    Article  CAS  Google Scholar 

  95. Arita T, Kurainitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K, Esato K. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 50: 1267–1269, 1995.

    Article  PubMed  CAS  Google Scholar 

  96. Patterson GA, Ginsberg RJ, Poon Y, et al. A prospective evaluation of magnetic resonance imaging, computed tomography and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 94: 679–684, 1987.

    PubMed  CAS  Google Scholar 

  97. Seely JM, Mayo JR, Miller RR, et al. T1 lung cancer: Prevalence of mediastinal nodal metastases and diagnostic accuracy of CT. Radiology 186: 129–132, 1993.

    PubMed  CAS  Google Scholar 

  98. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JO, Moore EH, Wain JC, Mathisen DJ, Grillo HC. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 182: 319–323, 1992.

    PubMed  CAS  Google Scholar 

  99. Gallardo JFM, Naranjo FB, Cansino MT, Rodriguez-Panadero F. Validity of enlarged mediastinal nodes as markers of involvement by non-small cell lung cancer. Am Rev Respir Dis 146: 1210–1212, 1992.

    Google Scholar 

  100. Gdeede A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 10: 1547–1551, 1997.

    Article  Google Scholar 

  101. Dillemans B, Deneffe G, Verschakelen J, et al. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardio Thorac Surg 8: 37–42, 1994.

    Article  CAS  Google Scholar 

  102. Arita T, Kuramitsu T, Kawamura M, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 50: 1267–1269, 1995.

    Article  PubMed  CAS  Google Scholar 

  103. Pearson FG. Staging of the mediastinum: role of mediastinoscopy and computed tomography. Chest 103(4): 346S–348S, 1993.

    Article  PubMed  CAS  Google Scholar 

  104. Libshitz HI, McKenna RJ Jr, Haynie TP, et al. Mediastinal evaluation in lung cancer. Radiology 151: 295–299, 1984.

    PubMed  CAS  Google Scholar 

  105. Staples CA, Muller NL, Miller RR, et al. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 167: 367372, 1988.

    Google Scholar 

  106. Oliver TW, Bernardino ME, Miller JI, et al. Isolated adrenal masses in non-small cell bronchogenic carcinoma. Radiology 153: 217–218, 1984.

    PubMed  Google Scholar 

  107. Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Clin Oncol 9: 1462–1466, 1991.

    PubMed  CAS  Google Scholar 

  108. Sandler MA, Pearlberg JL, Madrazo BL, Gitschlag KF, Gross SC. Computed tomographic evaluation of the adrenal gland in the preoperative assessment of bronchogenic carcinoma. Radiology 145: 733–736, 1982.

    PubMed  CAS  Google Scholar 

  109. Allard P, Yankaskas BC, Fletcher RH, et al. Sensitivity and specificity of computed tomography for the detection of adrenal metastatic lesions among 91 autopsied lung cancer patients. Cancer 66: 457–462, 1990.

    Article  PubMed  CAS  Google Scholar 

  110. Silverman SG, Mueller PR, Pinkney LP, et al. Predictive value of image-guided adrenal biopsy: analysis of results of 101 biopsies. Radiology 187: 715–718, 1993.

    PubMed  CAS  Google Scholar 

  111. Pagani JJ. Non-small cell lung carcinoma adrenal metastases computed tomography and percutaneous cancer. Cancer 53: 1058–1060, 1984.

    Article  PubMed  CAS  Google Scholar 

  112. Bernardino M, Walther M, Phillips V, et al. CT-guided adrenal biopsy: accuracy, safety, and indications. AJR 144: 67–69, 1985.

    PubMed  CAS  Google Scholar 

  113. Michel F, Soler M, Imhof E, et al. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 46: 469–473, 1991.

    Article  PubMed  CAS  Google Scholar 

  114. Tarver RD, Richmond BD, Kratte EC. Cerebral metastases from lung carcinomas: neurological and CT correlation. Radiology 153: 689–692, 1984.

    PubMed  CAS  Google Scholar 

  115. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med 149: 1076–1080, 1989.

    Article  PubMed  CAS  Google Scholar 

  116. Newman SJ, Hansen HH. Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33: 492–496, 1974.

    Article  PubMed  CAS  Google Scholar 

  117. Hooper R, Tenholder M, Underwood G, et al. Computed tomographic scanning of the brain in initial staging of bronchogenic carcinoma. Chest 85: 774–776, 1984.

    Article  PubMed  CAS  Google Scholar 

  118. Mintz BJ, Tuhrim S, Alexander S, et al. Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest 86: 850–853, 1984.

    Article  PubMed  CAS  Google Scholar 

  119. Warren WH, Faber LP. Bronchoscopic evaluation of the lungs and tracheobronchial tree, in Shields TW (ed): General Thoracic Surgery 250–262, Williams & Wilkins & Wilkins, Baltimore, 1994.

    Google Scholar 

  120. Stanley JH, Fish GD, Andriole JG, Gobien RP, Betsill WL, Laden SA, et al. Lung lesions: cytologic diagnosis by fine-needle biopsy. Radiology 162: 389–391, 1987.

    PubMed  CAS  Google Scholar 

  121. The Canadian Lung Group: Investigation for mediastinal disease in patients with apparently operable lung cancer. Ann Thorac Surg 60: 1382–1389, 1995.

    Article  Google Scholar 

  122. Daly BDT, Mueller JD, Faling LJ, Diehl JT, Bankoff MS, Karp DD, Rand WM. N2 lung cancer: Outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg 105(5): 904–911, 1993.

    PubMed  CAS  Google Scholar 

  123. Gdeddo A, Van Schil P, Corthouts B, et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 10(7): 1552–1558, 1997.

    Article  Google Scholar 

  124. Ginsberg RJ, Rice TW, Goldberg M, et al. Extended mediastinoscopy. J Thorac Cardiovasc Surg 94: 673–678, 1987.

    PubMed  CAS  Google Scholar 

  125. McNeil TM, Chamberlain JM. Diagnostic anterior mediastinotomy. Ann Thorac Surg 2: 532, 1966.

    Article  Google Scholar 

  126. Kondo D, Imaizumi M, Abe T, Naruke T, Suemasu K. Endoscopie ultrasound examination for mediastinal lymph node metastases of lung cancer. Chest 98: 586–593, 1990.

    Article  PubMed  CAS  Google Scholar 

  127. Silvestri GA, Hoffman BJ, Bhutani MS, Hawes RH, Coppage L, Sanders-Cliette A, Reed CE. Endoscopie ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 61: 1441–1446, 1996.

    Article  PubMed  CAS  Google Scholar 

  128. McCann J. PET scans approved for detecting metastatic non-small cell lung cancer. J Natl Cancer Inst 90(2): 94–96, 1998.

    Article  PubMed  CAS  Google Scholar 

  129. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, Bland W, Williams AJ. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 153: 417–421, 1996.

    PubMed  CAS  Google Scholar 

  130. Kutlu C, Pastorino U, Maisey M, et al. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer 21: 177–184, 1998.

    Article  PubMed  CAS  Google Scholar 

  131. Valk PE, Parnds TR, Hopkins DM, Haseman MK, Hoeb GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body position emission tomographic imaging. Ann Thorac Surg 60: 1573–1582, 1995.

    Article  PubMed  CAS  Google Scholar 

  132. Eberhadt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Udach V, Greschuchna D, Konietzko N, Sack H, Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: Mature results of a Phase II trial. J Clin Oncol 16(2): 622–634, 1998.

    Google Scholar 

  133. Venugopal P, Bonomi P, Ali A, Patel S, Faber LP, Lincoln S, LaFollette S, Priesler H. Correlation of positron emission tomography (PET) scan, computerized tomographic (CT) scan and histologic response to combined modality chemoradiotherapy (CT/RT) in Stage III non-small cell lung cancer.

    Google Scholar 

  134. Vansteenkoste JF, Stroobants SG, DuPont J, DeLeyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA, Demedts MG. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-position Emission Tomography Scan in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol 17: 3201–3206, 1999.

    Google Scholar 

  135. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nacckaerts KL, Mortelmans LA, Leuven Lung Cancer Group. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases. Chest 112: 1480–1486,1997.

    Article  PubMed  CAS  Google Scholar 

  136. Mentzer SJ. Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Hematol Oncol Clin North Am 11(3): 435–447, 1997.

    Article  PubMed  CAS  Google Scholar 

  137. Nabi HA, Steinbrenner L, Lamonica D, Spaulding M. The use of positron emission tomography. Proc Am Soc Clin Oncol 15: A-1204, 1996 (abstract).

    Google Scholar 

  138. Dewan N, Shehan C, Reeb S, et al. Likelihood of malignancy in a solitary pulmonary nodule comparison of bayesian analysis and results of FDG PET scan. Chest 112: 416–422, 1997.

    Article  PubMed  CAS  Google Scholar 

  139. Patz E Jr, Lowe V, Goodman P, et al. Thoracic nodal staging with positron emission tomography (PET) and 18-F-2-fluoro-2-deoxy-D-glucose in patients with bronchogenic carcinoma. Chest 108: 1617–1621, 1995.

    Article  PubMed  Google Scholar 

  140. Gupta N, Gill H, Graeber G, et al. Dynamic positron emission tomography with F-18-fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 114: 1105–1111, 1998.

    Article  PubMed  CAS  Google Scholar 

  141. Steinert H, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiol 202: 441–446, 1997.

    CAS  Google Scholar 

  142. Wahl R, Quint L, Greenough R, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiol 191: 371–377, 1994.

    CAS  Google Scholar 

  143. Ichiya Y, Kuwabara Y, Otsuka M. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32: 1655–1660, 1991.

    PubMed  CAS  Google Scholar 

  144. Frank A, Letkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32: 1495–1512, 1995.

    Article  PubMed  CAS  Google Scholar 

  145. Kubota K, Yamada S, Ishiwata K, et al. Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer. Clin Nucl Med 17: 877–881, 1992.

    Article  PubMed  CAS  Google Scholar 

  146. Kim E, Chung S, Haynie TP. Differentiation of residual or recurrent tumors from post-treatment changes with F-18-FDG PET. RadioGraphic 12: 269–279, 1992.

    CAS  Google Scholar 

  147. Patz E, Lowe V, Hoffman J, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiol 191: 379–382,1994.

    Google Scholar 

  148. Kerstine KH, Trapp JF, Croft DR, et al. Comparison of positron emission tomography (PET) and computed tomography (CT) to identify N2 and N3 disease in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 458, 1998 (abstract 1762).

    Google Scholar 

  149. Shields TW. The significance of ipsilateral mediastinal lymph node metastases (N2 disease) in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 99: 48–53, 1990.

    PubMed  CAS  Google Scholar 

  150. Goldstraw P, Mannam GC, Kaplan DK, Mitchail P. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastases (N2 disease). J Thorac Cardiovasc Surg 107: 19–28, 1994.

    PubMed  CAS  Google Scholar 

  151. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 67: 1037–1049, 1987.

    PubMed  CAS  Google Scholar 

  152. Mitsukuoka M, Hayashi A, Takamori S, Nagamatsu Y, Matsuo T, Kakegawa T. The significance of lymph nodes (LN) dissection through median sternotomy for left lung cancer. Lung Cancer 11(suppl 1): 149, 1994.

    Google Scholar 

  153. Levasseur PH, Regnard JF. Long term results after surgery for N2 non-small cell lung cancer. Presented at the International Association for the Study of Lung Cancer (IASCC) Workshop, Burges, Belgium, June 17–21, 1990.

    Google Scholar 

  154. Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastases. Ann Thorac Surg 46: 603–610, 1988.

    Article  PubMed  CAS  Google Scholar 

  155. Moores DW, McKneally MF. Treatment of stage I lung cancer (T1NOMO, T2NOM0). Surg Clin North Am 67: 937–943, 1987.

    PubMed  CAS  Google Scholar 

  156. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in non-small cell lung cancer: Systemic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352: 257–263, 1998.

    Article  Google Scholar 

  157. Niiranen A, Witamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhonen S. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: A randomized study. J Clin Oncol 10: 1927–1932, 1992.

    PubMed  CAS  Google Scholar 

  158. Wada H, Hitomi S, Teramatsu T, et al. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol 114: 1048–1054, 1996.

    Google Scholar 

  159. Warren WH, Faber LP. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. J Thorac Cardiovasc Surg 107: 1087–1094, 1994.

    PubMed  CAS  Google Scholar 

  160. Yano T, Yokoyama H, Yoshino I, Tayama K, Asoh H, Hata K, et al. Results of a limited resection for compromised or poor-risk patients with clinical stage I non-small cell carcinoma of the lung. J Am Coll Surg 181: 33–37, 1995.

    PubMed  CAS  Google Scholar 

  161. Ayoub J, Vigneault J, Hanley A, et al. The Montreal multi-center trial in operable non-small cell lung cancer (NSCLC): a multivariate analysis of the predictors of relapse. Proc Am Soc Clin Oncol 10: 247, 1991 (abstract).

    Google Scholar 

  162. Mountain CF. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 108: 246–254, 1995.

    Article  PubMed  CAS  Google Scholar 

  163. Martini N, Flehinger BJ, Nagasaki F, Hart B. Prognostic significance of N1 disease in carcinoma of the lung. J Thorac Cadiovasc Surg 86: 646–653, 1983.

    CAS  Google Scholar 

  164. Holmes EC. Treatment of stage II lung cancer (T1N1, T2N1). Surg Clin North Am 67: 945–949, 1987.

    Google Scholar 

  165. Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 107: 1398–1402, 1994.

    PubMed  CAS  Google Scholar 

  166. Weisenberger TH, Gail M, Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 315: 1377–1381, 1986.

    Article  Google Scholar 

  167. Holmes EC, Gail M, Lung Cancer Study Group. Surgical adjuvant therapy for stage II and III adenocarcinoma and large cell undifferentiated carcinoma. J Clin Onco14: 710–715, 1986.

    Google Scholar 

  168. Lad T, Rubinstein A, Sadeghi A, et al. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. J Clin Oncol 6: 9–17, 1988.

    Google Scholar 

  169. Keller S, Adak S, Wagner H, Herskovic A, Brooks B, Perry M, Livingston R. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stage I and stage IIIA non-small cell lung cancer. Proc Am Soc Clin Oncol 18: 465a, 1999 (abstract A-1793).

    Google Scholar 

  170. Pichler JM, Pairolero PC, Weiland LH, et al. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg 34: 684–691, 1982.

    Article  Google Scholar 

  171. Patterson GA, Ilves R, Ginsberg PJ, et al. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. Ann Thorac Surg 34: 692–697, 1982.

    Article  PubMed  CAS  Google Scholar 

  172. Rosell R, Goméz-Codina J, Camps C, Maestre J, Padille J, Cantró A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330: 153–158, 1994.

    Article  PubMed  CAS  Google Scholar 

  173. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86: 673–680, 1994.

    Article  PubMed  CAS  Google Scholar 

  174. DePierre A, Milleron B, Moro D, Chaveb S, Braun D, Quoix E, et al. Phase III trial of neo-adjuvant chemotherapy in resectable stage I (except T1NO) II, IIIA non-small cell lung cancer: French experience. Proc Am Soc Clin Oncol 18: 465a, 1999 (abstract A-1792).

    Google Scholar 

  175. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323: 940–945, 1990.

    Article  PubMed  CAS  Google Scholar 

  176. Dillman RO, Seagren SL, Herndon J, Green MR, et al. Randomized trial of induction chemotherapy plus radiation therapy (RT) vs RT alone in stage III non-small cell lung cancer: five-year follow up of CALGB 84–33. Proc Am Soc Clin Oncol 12: 329, 1993 (abstract).

    Google Scholar 

  177. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary advanced results of a phase III trial of regionally unresectable non-small cell lung cancer. J Natl Cancer Inst 87: 198–205, 1995.

    Article  PubMed  CAS  Google Scholar 

  178. LeChevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417–423, 1990.

    Article  Google Scholar 

  179. LeChevalier T, Arriagada R, Quoix E, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 84: 58, 1992 (letter).

    Article  CAS  Google Scholar 

  180. Cullen MA, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188–3194, 1999.

    PubMed  CAS  Google Scholar 

  181. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326: 524–530, 1992.

    Article  PubMed  CAS  Google Scholar 

  182. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 13: 452–458, 1995.

    PubMed  CAS  Google Scholar 

  183. Jeremic B, Shibamoto Y, Acimovic L, Milisarljenic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin-etoposide for stage III non-small cell lung cancer. J Clin Oncol 14: 1065–1070, 1996.

    PubMed  CAS  Google Scholar 

  184. Furuse K, Fukuoka F, Takada Y, et al. Phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable non-small cell lung cancer. J Clin Oncol 17: 2692–2699, 1999.

    PubMed  CAS  Google Scholar 

  185. Saunders MI, Dische S. Continuous hyperfractionated accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 19: 1211–1215, 1990.

    Article  PubMed  CAS  Google Scholar 

  186. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. Lancet 350: 161–165, 1997.

    Article  PubMed  CAS  Google Scholar 

  187. Martini N, Kris M, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIA (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55: 1365–1374, 1993.

    Article  PubMed  CAS  Google Scholar 

  188. Burkes RL, Shepherd FA, Ginsberg RJ, et al. Induction chemotherapy with MVP in patients with stage III (T1–3,N2,M0) unresectable non-small cell lung cancer. The Toronto experience. Proc Am Soc Clin Oncol 13: 327, 1994 (abstract).

    Google Scholar 

  189. Langer CJ, Curran WJ, Keller SM, et al. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA NSCLC. Int J Rad Onc Biol Phys 26: 469–478, 1993.

    Article  CAS  Google Scholar 

  190. Rusch VW, Albain KS, Crowley JJ, et al. Surgical resection of stage IIIA and IIIB non-small cell lung cancer after concurrent induction chemoradiotherapy. J Thorac Cardiovasc Surg 105: 97–106, 1993.

    PubMed  CAS  Google Scholar 

  191. Albain K, Rusch V, Crowley J, Rice T, Turrisi A, Weick J, et al. Long term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group study 8805. Proc Am Soc Clin Oncol 18: A-1801, 1999.

    Google Scholar 

  192. Byhardt R, Scott C, Sause W, et al. Response, toxicity, failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) and radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC). Proc 396’ Ann Am Soc Ther Rad Oncol Mtg 195: 1997 (abstract 120).

    Google Scholar 

  193. Cartei G, Cartei F, Cantrone A, Cansarano D, Genco G, Tobaldin A, Interlandi G, Giraldi T. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care vs supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 85: 794–800, 1993.

    Article  PubMed  CAS  Google Scholar 

  194. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials BMJ 311: 899–909, 1995.

    Article  Google Scholar 

  195. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613, 1989.

    PubMed  CAS  Google Scholar 

  196. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8: 1556–1562, 1990.

    PubMed  CAS  Google Scholar 

  197. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414–420, 1981.

    PubMed  CAS  Google Scholar 

  198. Klastersky J, Sculier JP, Ravez P, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 4: 1780–1786, 1986.

    PubMed  CAS  Google Scholar 

  199. Shinkai T, Saijo N, Eguchi K, et al. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res77:782–789, 1986.

    PubMed  CAS  Google Scholar 

  200. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459–2465, 1998.

    PubMed  CAS  Google Scholar 

  201. Sandler A, Nemunaitis J, Dehnam C, et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 454a, 1998 (abstract).

    Google Scholar 

  202. von Pawel J, von Roemeling R. Survival benefit from Triazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients final results from the international phase III CATAPULT I trial. Proc Am Soc Clin Oncol 17: 454a, 1998 (abstract 1749).

    Google Scholar 

  203. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 15: 382, 1996 (abstract 1145).

    Google Scholar 

  204. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360–367, 1994.

    PubMed  Google Scholar 

  205. Peng R-P, Chen YM, Ming Liu J, Tsai C-M, Lin W-C, Yang K-Y, Whang Peng J. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 15(5): 2097–2102, 1997.

    Google Scholar 

  206. Manegold C, Bergman B, Chemaissani et al. Single agent gemcitabine versus cisplatin-etoposide: Early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 8(6): 525–529, 1997.

    Article  PubMed  CAS  Google Scholar 

  207. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66–72, 1999.

    Article  Google Scholar 

  208. Murray N, Coy P, Pater J, Hodson I, Arnold A, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11: 336–344, 1993.

    PubMed  CAS  Google Scholar 

  209. Hansen HH. Management of small cell cancer of the lung. Lancet 339: 846–849, 1992.

    Article  PubMed  CAS  Google Scholar 

  210. Dearing MP, Steinberg SM, Phelps R, et al. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 8: 1042–1049, 1990.

    PubMed  CAS  Google Scholar 

  211. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer: an analysis of the 2850 patient Southwest Oncology Group data base. J Clin Oncol 8: 1563–1574, 1990.

    PubMed  CAS  Google Scholar 

  212. Ihde DC, Glatstein EJ, Pass HI. Small-cell lung cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 911–950.

    Google Scholar 

  213. Livingston RB, McCracken JD, Trauft CJ, et al. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. Chest 81: 208–215, 1982.

    Article  PubMed  CAS  Google Scholar 

  214. Giannone L, Johnson DH, Hande KR, Greco FA. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med 106: 386–389, 1987.

    PubMed  CAS  Google Scholar 

  215. Matthews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumors in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 4: 63–67, 1973.

    CAS  Google Scholar 

  216. Williams CJ, McMillan I, Lea R, Mead G, Thompson J, Sweetenham J, Herbert A, Jeffreys M, Buchanan R, Whitehouse JM. Surgery after initial chemotherapy for localized small cell carcinoma of the lung. J Clin Oncol 5: 1579–1588, 1987.

    PubMed  CAS  Google Scholar 

  217. Shields TW, Higgins GA, Matthews MJ, Heehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 84: 481–488, 1982.

    PubMed  CAS  Google Scholar 

  218. Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical treatment for limited small cell lung cancer. The university of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Surg 101: 385–393, 1991.

    PubMed  CAS  Google Scholar 

  219. Shah SS, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment of small-cell lung cancer. Ann Thorac Surg 54: 498–501, 1992.

    Article  PubMed  CAS  Google Scholar 

  220. Baldeyrou P, Marrash R, LeChevalier T, Arriagada R. L’endoscopie bronchique dans le bilan diagnostique et evolutif des cancers broncho-pulmonaires a petites cellules. Bull Cancer 74: 511–515, 1987.

    PubMed  CAS  Google Scholar 

  221. Sagman U, Feld R, Evans WK, et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol 9: 954–961, 1991.

    PubMed  CAS  Google Scholar 

  222. Shepherd FA. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 5: 310–322, 1993.

    Article  PubMed  CAS  Google Scholar 

  223. Hansen HH. Diagnosis in metastatic sites. In: Straus MJ, ed. Lung cancer clinical diagnosis and treatment. New York: Grune & Stratton, 185–200, 1983.

    Google Scholar 

  224. Newman SJ, Hansen HH. Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33: 492–496, 1974.

    Article  PubMed  CAS  Google Scholar 

  225. Tritz DB, Doll DC, Ringenberg QS, et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 63: 763–766, 1989.

    Article  PubMed  CAS  Google Scholar 

  226. Levitan N, Byrne RE, Bromer RH, et al. The value of the bone scan and bone marrow biopsy in staging small cell lung cancer. Cancer 56(3): 652–654, 1985.

    Article  PubMed  CAS  Google Scholar 

  227. Ihde D, Simms E, Matthews M, Cohen MH, Bunn PA, Minna JD. Bone marrow metastases in small cell carcinoma of the lung. Blood 53: 677–686, 1978.

    Google Scholar 

  228. Zych J, Polowiec Z, Wiatr E, Broniek A, Rowinska-Zakrzewska E. The prognostic significance of bone marrow metastases in small cell lung cancer patients. Lung Cancer 10: 239–245, 1993.

    Article  PubMed  CAS  Google Scholar 

  229. Ihde DC, Hansen HH. Staging procedures and prognostic factors in small cell carcinoma of the lung. In: Greco FA, Oldham RK, Bunn PA, eds. Small cell lung cancer. New York: Grune & Stratton 261–283, 1981.

    Google Scholar 

  230. Mulshine JL, Makuch RW, Johnston-Early A, et al. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol 2: 733–741, 1984.

    PubMed  CAS  Google Scholar 

  231. Hirsch FR, Paulson OB, Hansen HH, Larsen SO. Intracranial metastases in small cell carcinoma of the lung, prognostic aspects. Cancer 51: 529–533, 1983.

    Article  PubMed  CAS  Google Scholar 

  232. Hirsch FR, Paulson OB, Hansen HH, Vraa-Jensen J. Intracranial metastases in small cell carcinoma of the lung, correlation of clinical and autopsy findings. Cancer 50: 2433–2437, 1982.

    Article  PubMed  CAS  Google Scholar 

  233. Nugent JL, Bunn PA, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma. Cancer 44: 1885–1893, 1979.

    Article  PubMed  CAS  Google Scholar 

  234. Crane JM, Nelson MJ, Ihde DC, et al. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. J Clin Oncol 2: 1017–1024, 1984.

    PubMed  CAS  Google Scholar 

  235. Hardy J, Smith I, Cherryman G, et al. The value of computed tomographic scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. Br J Cancer 62: 684–686, 1990.

    Article  PubMed  CAS  Google Scholar 

  236. Akoun GM, Scarna HM, Milleron BJ, Bénichou MP, Herman DP. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest 87: 39–43, 1985.

    Article  PubMed  CAS  Google Scholar 

  237. Jaques GJ, Bepler G, Holle R, Wolf M. Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase, and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer 62: 125–134, 1988.

    Article  PubMed  CAS  Google Scholar 

  238. Joorgensen LGM, Osterlind K, Hansen HH, Cooper EH. The prognostic influence of serum neuron specific enolase in small cell 1 ung cancer. Br J Cancer 58: 805807, 1988.

    Google Scholar 

  239. Gronowitz JS, Bergstrom R, Nou E, et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66: 722–732, 1990.

    Article  PubMed  CAS  Google Scholar 

  240. Harding M, McAllister J, Hulks G, et al. Neurone specific enolase (NSE) in small cell 1 ung cancer: a tumour marker of prognostic significance? Br J Cancer 61: 605–607, 1990.

    Article  PubMed  CAS  Google Scholar 

  241. Heekstra R, Splintor TAW. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 64: 369–372, 1991.

    Article  Google Scholar 

  242. Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 67: 760–766, 1993.

    Article  PubMed  CAS  Google Scholar 

  243. Tokuraku M, Sato H, Murakami S, et al. Activation of precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase [MT-MMP] and with lymph node metastasis. Int J Cancer 64: 355–359, 1995.

    Article  PubMed  CAS  Google Scholar 

  244. Kawano N, Osawa H, Ito T, et al. Expression of gelatinase-A, tissue inhibitor of metalloproteinase-2, matrilysin, and trypsin(ogen) in lung neoplasms: An immunohistochemical study. Hum Pathol 28: 613–622, 1997.

    Article  PubMed  CAS  Google Scholar 

  245. Radic PA, Mathews MJ, Ihde DC, et al. The clinical behavior of “mixed” small cell/large cell bronchogenic carcinoma compared to “pure” small cell subtypes. Cancer 50: 2894–2902, 1982.

    Article  Google Scholar 

  246. Aisner SC, Finkelstein DM, Ettinger DS, et al. The clinical significance of variant morphology small cell carcinoma of the lung. J Clin Oncol 8: 402–408, 1990.

    PubMed  CAS  Google Scholar 

  247. Sehested M, Hirsch FR, Osterlind K, et al. Morphologic variations of small cell lung cancer: a histopathologic study of pretreatment and post treatment specimens in 104 patients. Cancer57:804–807, 1986.

    Article  PubMed  CAS  Google Scholar 

  248. Osterlind K, Andersen PK. Prognostic factors in small cell 1 ung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 46: 4189–4194, 1986.

    PubMed  CAS  Google Scholar 

  249. Ihde DC, Makuch RW, Carney DN, et al. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 123: 500–507, 1981.

    PubMed  CAS  Google Scholar 

  250. Wolf M, Holle R, Hans K, et al. Analysis of prognostic factors in 766 patients with small cell lung cancer: the role of sex as a predictor for survival. Br J Cancer 63: 986–992, 1991.

    Article  PubMed  CAS  Google Scholar 

  251. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 7: 344–354, 1989.

    PubMed  CAS  Google Scholar 

  252. Chute JP, Venzon D, Hankins L, et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72: 901–912, 1997.

    PubMed  CAS  Google Scholar 

  253. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4: 31–42,1973.

    CAS  Google Scholar 

  254. Aisner J. Extensive disease small-cell lung cancer: The thrill of victory; the agony of defeat. J Clin Oncol 14: 658–665, 1996.

    PubMed  CAS  Google Scholar 

  255. Johnson DE, Turrisi AT, Chang AY, Blum R, Bonomi P, Ettinger D, Wagner H. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small cell lung cancer: a pilot study of the Eastern Cooperative Group. J Clin Oncol 11: 879–884, 1993.

    PubMed  CAS  Google Scholar 

  256. McCracken JD, Janaki LM, Crowley JJ, Taylor SA, Giri PG, Weiss GB, Gordon W Jr, Baker LH, Mansouri A, Kuebler JP. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol 8: 892–898, 1990.

    PubMed  CAS  Google Scholar 

  257. Bunn PA Jr, Lichter AS, Makuch RW, Cohen M, Veach SR, Matthews MJ, Johnston Anderson A, Edison M, Glatstein E, Minna JD, Ihde DC. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small-cell lung cancer. A prospective, randomized trial. Ann Intern Med 106: 655–662, 1987.

    PubMed  Google Scholar 

  258. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265–271, 1999.

    Article  PubMed  CAS  Google Scholar 

  259. Johnson BE, Salem C, Nesbitt J, et al. Limited stage small-cell 1 ung cancer (SCLC) treated with concurrent BID chest radiotherapy (RT) and etoposide/cisplatin (VP/Pt) followed by chemotherapy (CT) selected by in vitro drug sensitivity testing (DST). Proc Am Soc Clin Oncol 10: 240, 1991(abstract).

    Google Scholar 

  260. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive stage small cell lung cancer: perceptible progress. J Clin Oncol 17: 1794–1801, 1999.

    PubMed  CAS  Google Scholar 

  261. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327: 1618–1624, 1992.

    Article  PubMed  CAS  Google Scholar 

  262. Takada M, Fukuoka M, Furuse K, et al. Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) for limited stage (LS) small-cell lung cancer (SCLC): preliminary results of the Japan Clinical Oncology Group (JCOG). Proc Am Soc Clin Oncol 15: 372, 1996 (abstract)

    Google Scholar 

  263. Murray N, Coy P, Pater JL, et al. The importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 11: 336–344, 1993.

    PubMed  CAS  Google Scholar 

  264. Auperin A, Arriagada R, Pignon J-P, LePechoux C, Gregor A, Stephens RJ, Kristjansen PEG, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Eng J Med 341: 476–484, 1999.

    Article  CAS  Google Scholar 

  265. Fleck JF, Einhorn LH, Lauer RC, Schultz SM, Miller ME. Is prophylactic cranial irradiation indicated in small-cell lung cancer? J Clin Oncol 8: 209–214, 1990.

    PubMed  CAS  Google Scholar 

  266. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small-cell lung cancer: results of a multicentre randomized trial. Eur J Cancer 33: 1752–1758, 1998.

    Article  Google Scholar 

  267. Komaki R, Byhardt RW, Anderson T, et al. What is the lowest effective biologic dose for prophylactic cranial irradiation? Am J Clin Oncol 8: 523–527, 1985.

    Article  PubMed  CAS  Google Scholar 

  268. Shepherd FA, Ginsberg RT, Feld R, Evans WK, Johansen E. Surgical treatment for limited small cell lung cancer. J Thorac Cardiovasc Surg 101: 385–393, 1991.

    PubMed  CAS  Google Scholar 

  269. Jacoulet P, Depierre A, Moro D, Riviere A, Milleron B, Quoix E, et al. Long-term survivors of small cell lung cancer (SCLC): a French multicenter study. Ann Oncol 8(10): 1009–1014, 1997.

    Article  PubMed  CAS  Google Scholar 

  270. Heyne KH, Lippman SM, Lee JS, et al. The incidence of second primary tumors in long-term survivors of small cell lung cancer. J Clin Oncol 10: 1519–1524, 1992.

    PubMed  CAS  Google Scholar 

  271. Lassen O, Osterlind K, Hansen M. Long-term survival in small cell lung cancer: post-treatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 13: 1215–1220, 1995.

    PubMed  CAS  Google Scholar 

  272. Sagman U, Lishner M, Maki E, et al. Second primary malignancies following diagnosis of small cell lung cancer. J Clin Oncol 10: 1525–1533, 1992.

    PubMed  CAS  Google Scholar 

  273. Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The incidence of second primary tumors in long term survivors of small cell lung cancer. J Clin Oncol 10: 1519–1524, 1992.

    PubMed  CAS  Google Scholar 

  274. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 119: 383–390, 1993.

    PubMed  CAS  Google Scholar 

  275. Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973–1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10: 515–539, 1984.

    Article  PubMed  CAS  Google Scholar 

  276. Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N. Intensive weekly chemotherapy for the treatment of extensive-stage small cell lung cancer. J Clin Oncol 9: 1632–1638, 1994.

    Google Scholar 

  277. Grant SC, Kris MG. Phase II trials in small cell lung cancer: shouldn’t we be doing better? J Natl Cancer Inst 84: 1058–1059, 1992.

    Article  PubMed  CAS  Google Scholar 

  278. Aisner J. Identification of new drugs in small cell lung cancer: phase II agents first? Cancer Treat Rep 71: 1131–1133, 1988.

    Google Scholar 

  279. Johnson DH. New drugs in the management of small cell lung cancer. 5: 221–231, 1989.

    Google Scholar 

  280. Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, Bonomi P. Justification for evaluating new anticancer drugs in selected untreated patients with extensive stage small cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 84: 1077–1084, 1992.

    Article  PubMed  CAS  Google Scholar 

  281. Grant SC, Gralla RJ, Kris MG, Orazem F, Kitsis RA. Single agent chemotherapy trials in small cell lung cancer. 1970–1990: the case for studies in previously treated patients. J Clin Oncol 10: 484–498, 1992.

    PubMed  CAS  Google Scholar 

  282. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8: 230–240, 1990.

    PubMed  CAS  Google Scholar 

  283. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83: 855–861, 1991.

    Article  PubMed  CAS  Google Scholar 

  284. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 1–11, 1992.

    Google Scholar 

  285. Feld M, Evans WK, Coy P, Hodson I. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung. J Clin Oncol 5: 1401–1409, 1987.

    PubMed  CAS  Google Scholar 

  286. Maksymiuk AW, Jett JR, Earle JD, et al. Sequencing and schedule effects of cisplatin plus etoposide in small cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 12: 70–76, 1994.

    PubMed  CAS  Google Scholar 

  287. Loehrer PJ, Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol 13: 2594–2599, 1995.

    PubMed  CAS  Google Scholar 

  288. Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell 1 ung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 14: 135–141, 1996.

    PubMed  CAS  Google Scholar 

  289. Miller AA, Herndon JE II, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13: 1871–1879, 1995.

    PubMed  CAS  Google Scholar 

  290. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83: 855–861, 1991.

    Article  PubMed  CAS  Google Scholar 

  291. Johnson DH, Einhorn L, Birch R, et al. A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Onco15: 1731–1738, 1987.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center Philadelphia, PA, 19111, USA

    Corey J. Langer M.D.

Authors
  1. Corey J. Langer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland, USA

    David S. Ettinger MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Langer, C.J. (2001). Staging and Prognosis in Lung Cancer: Making the Complex Accessible. In: Ettinger, D.S. (eds) Thoracic Oncology. Cancer Treatment and Research, vol 105. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1589-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1589-0_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5629-5

  • Online ISBN: 978-1-4615-1589-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation